J&J's Janssen Pharmaceutica to Develop MDx Assays for Biocartis' Integrated NAT Platform

Janssen becomes the third assay content provider for Biocartis' integrated "sample-to-answer" nucleic acid testing platform as the company drives toward a full commercial launch in the second half of 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.